Oct 11, 2017
Program available online at WOSU Radio, hosted by Ann Fisher.
In case you missed it, last week on the morning edition of NPR News, Ed Silverman, senior writer and Pharmalot columnist, STAT News, and Dr. William Carey, senior hepatologist in the Department of Gastroenterology, Cleveland Clinic, sat down to discuss cost and cure rates of the newly approved drugs used to treat all HCV genotypes.
Topics
Estimated 180,000 people with HCV go untreated
Gilead, AbbVie and Merck - Cost, price competition, treatment duration, and HCV cure rates
Disease progression
HCV Generics
The interview is about 15 minutes long, starting point is at 15.35, or fifteen minutes into the program.
Link
Listen Live - NPR News
Of Interest - On This Blog
Hepatitis C Timeline
First recorded references to hepatitis epidemics, to the 1989 discovery of the hepatitis C virus, as well as HCV discontinued agents, ending with the FDA approved treatments used today.
No comments:
Post a Comment